Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients
Diabetes, Obesity and Metabolism Jan 26, 2019
Singh P, et al. - In this study, researchers tested the effectiveness and safety of dulaglutide for the management of type 2 diabetes in solid organ transplant (SOT) recipients. From October 30, 2014, to January 1, 2018, a retrospective chart review of SOT recipients with type 2 diabetes who were under treatment with dulaglutide was performed. Findings revealed that the mean paired difference for insulin reduction before and after dulaglutide treatment was 5.94 units. No increased risk of malignancy, cardiovascular morbidity, graft-failure or all-cause mortality was observed. Investigators reported that gastrointestinal manifestations were rare, even in advanced chronic kidney disease patients, and did not require changes in immunosuppressive agents. Dulaglutide can, therefore, be considered an important option for the management of diabetes in SOT.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries